Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy. Learn more about CYTK ...
Right now, the HALT Study is underway to provide the substantial evidence of effectiveness necessary for the full FDA approval of Felycin-CA1 (referred to as TRIV202 in HALT) for the management of ...
Extra scrutiny is warranted to identify the underlying causes of chest pain in patients with nonobstructive coronary disease ...
Patients with undiagnosed sleep disordered breathing and hypertrophic cardiomyopathy may have subclinical myocardial injury.
Invasive epicardial coronary physiologic assessment is increasingly performed to evaluate the hemodynamic significance of ...
Discover why Cytokinetics (CYTK) is a top BUY in precision cardiology. Learn about aficamten, its market potential, and ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common ...
Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...
Zacks Investment Research on MSN
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
Bristol Myers BMY announced that it will discontinue the late-stage Librexia study evaluating the efficacy and safety of ...
System of Care to Advance Care for the Most Commonly Inherited Heart DiseaseSOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback